
    
      The investigators investigate to evaluate the efficacy of alirocumab for in-stent
      neoatherosclerosis. The investigators enrolled the patient who performed drug eluting stent
      implantation and detected in-stent neoatherosclerosis by follow up optical coherence
      tomography, and categorized into two group; the patients with alirocumab and rosuvastatin the
      investigatorsre categorized alirocumab therapy group, and the patients with rosuvastatin
      alone were categorized standard statin therapy group.

      The investigators compare these two group for outcomes.
    
  